Outcomes of patients aged 70 years or younger with aggressive ATL at core hospitals for ATL treatment in Tokyo
International Journal of Hematology · 2026
DOI: 10.1007/s12185-025-04057-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Hematology, 2026. Verfasst von Junya Makiyama und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia-Lymphoma, Adult T-Cell. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Adult T-cell leukemia-lymphoma (ATL) is one of the most intractable peripheral T-cell neoplasms caused by human T-cell leukemia virus type I (HTLV-1) infection. Recently, the incidence of HTLV-1 infection and ATL has increased in non-endemic metropolitan areas in Japan. This retrospective study evaluated the clinical features and outcomes of patients with aggressive ATL aged 70 years or younger treated at a core hospital in Tokyo between 2004 and 2016. The median follow-up was 124.4 months for survivors. Among the 71 patients, 46 (64.8%) underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). The 3 year overall survival rate was 45.7% in allo-HSCT group versus 0% in non-allo-HSCT group. Patients who achieved complete/partial remission before allo-HSCT had a significantly better survival rate than those with stable/progressive disease (51.4% vs 27.3%). The 2 year cumulative incidence of relapse/progression and non-relapse mortality after allo-HSCT was 41.3% and 21.7%, respectively. In this study, a large percentage of patients underwent allo-HSCT and achieved favorable outcomes. As cases continue to rise in metropolitan areas, core hospitals will play a critical role in ATL treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, Japan. junya.makiyama@me.com.
- Department of Hematology, Sasebo City General Hospital, Nagasaki, Japan. junya.makiyama@me.com.
- Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, Japan.
- Department of Hematology, Kanto Rosai Hospital, Kanagawa, Japan.
- Department of Hematology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
- Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Zitieren
APA
Makiyama, J., Ohno, N., Jimbo, K., Kawamata, T., Yokoyama, K., Konuma, T., Kato, S., Takemura, T., Ito, A., Tanaka, T., Inamoto, Y., Fuji, S., Imai, Y., Takahashi, S., Nannya, Y., Tojo, A., Fukuda, T., & Uchimaru, K. (2026). Outcomes of patients aged 70 years or younger with aggressive ATL at core hospitals for ATL treatment in Tokyo. International Journal of Hematology. https://doi.org/10.1007/s12185-025-04057-2
Vancouver
Makiyama J, Ohno N, Jimbo K, Kawamata T, Yokoyama K, Konuma T, et al. Outcomes of patients aged 70 years or younger with aggressive ATL at core hospitals for ATL treatment in Tokyo. International Journal of Hematology. 2026. doi:10.1007/s12185-025-04057-2
BibTeX
@article{Makiyama2026,
author = {Makiyama, Junya and Ohno, Nobuhiro and Jimbo, Koji and Kawamata, Toyotaka and Yokoyama, Kazuaki and Konuma, Takaaki and Kato, Seiko and Takemura, Tomonari and Ito, Ayumu and Tanaka, Takashi and Inamoto, Yoshihiro and Fuji, Shigeo and Imai, Yoichi and Takahashi, Satoshi and Nannya, Yasuhito and Tojo, Arinobu and Fukuda, Takahiro and Uchimaru, Kaoru},
title = {Outcomes of patients aged 70 years or younger with aggressive ATL at core hospitals for ATL treatment in Tokyo},
journal = {International Journal of Hematology},
year = {2026},
doi = {10.1007/s12185-025-04057-2}
}
EUVIMED